Identification of GPD1L as a potential prognosis biomarker and associated with colorectal cancer progression

Colorectal cancer (CRC) ranks high in both global incidence and mortality rates. The discovery of potential biomarkers and therapeutic targets can effectively improve early diagnosis, treatment efficacy, and prognosis for CRC patients. Genes that were abnormally expressed in CRC tumors and associated with patients’ prognosis were first screened in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases; Clinical CRC samples were used to validate the results. The correlation between clinical characteristics and candidate genes, as well as their role in CRC cell proliferation, migration, invasion capability, and the cell cycle were analyzed. The study indicated that glycerol-3-phosphate dehydrogenase 1-like (GPD1L) was significantly down-regulated in CRC tumor tissues and served as an independent prognostic factor for OS and RFS of CRC patients. It was also associated with TNM staging, lymph node metastasis, tumor size, and tumor location. Inhibiting GPD1L expression significantly up-regulated the proliferation, migration, and invasion capabilities of CRC cells. GPD1L may serve as a prognostic biomarker for patients with CRC and participate in the regulation of CRC cell proliferation, migration, and invasion capability.